BI-1622 is an orally active, potent, and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. It demonstrates over 25-fold selectivity for HER2 compared to EGFR. BI-1622 exhibits high antitumor efficacy in vivo in xenograft mouse tumor models using engineered H2170 and PC9 cells, and it possesses a favorable agent metabolism and pharmacokinetics profile.
- Inhibits proliferation of HER2-dependent cell lines.
- Induces a dose-dependent decrease in pHER2 and pERK levels.
- Displays good permeability and no PgP-mediated efflux liability.
- Shows good in vitro clearance in mouse liver microsomes and mouse hepatocytes.
- Potently inhibited the proliferation of cancer cell lines dependent on amplified HER2 or an NRG-1 fusion.
- Shows moderate clearance, a moderate volume of distribution, and good to moderate bioavailability up to 68%.
- Inhibits tumor growth and oncogenic signaling.